OBJECTIVE: To estimate the prevalence, genotypes, and individual-level correlates of high-risk human papillomavirus (HPV) among women aged 57-85. METHODS: Community-residing women (N=1,550), aged 57-85, were drawn from a nationally representative probability sample. In-home interviews and biomeasures, including a self-collected vaginal specimen, were obtained between 2005 and 2006. Specimens were analyzed for high-risk HPV DNA using Hybrid Capture 2; of 1,028 specimens provided, 1,010 were adequate for analysis. All samples testing positive were analyzed for HPV DNA by L1 consensus polymerase chain reaction followed by type-specific hybridization. RESULTS: The overall population-based weighted estimate of high-risk HPV prevalence by Hybrid Capture 2 (Digene Corp.) was 6.0% (95% confidence interval 4.5- 7.9). Current marital and smoking status, frequency of sexual activity, history of cancer, and hysterectomy were associated with high-risk HPV positivity. Among high-risk HPV-positive women, 63% had multiple type infections. Human papillomavirus-16 or -18 was present in 17.4% of all high-risk HPV-positive women. The most common high-risk genotypes among high-risk HPV-positive women were HPV-61 (19.1%), -31 (13.1%), -52 (12.9%), -58 (12.5%), -83 (12.3%), -66 (12.0%), -51 (11.7%), -45 (11.2%), -56 (10.3%), -53 (10.2%), -16 (9.7%), and -62 (9.2%). Being married and having an intact uterus were independently associated with lower prevalence of high-risk HPV. Among unmarried women, current sexual activity and smoking were independently and positively associated with high-risk HPV infection. CONCLUSION: In this nationally representative population, nearly 1 in 16 women aged 57-85 was found to have high-risk HPV, and prevalence was stable across older age groups. LEVEL OF EVIDENCE: II.
OBJECTIVE: To estimate the prevalence, genotypes, and individual-level correlates of high-risk human papillomavirus (HPV) among women aged 57-85. METHODS: Community-residing women (N=1,550), aged 57-85, were drawn from a nationally representative probability sample. In-home interviews and biomeasures, including a self-collected vaginal specimen, were obtained between 2005 and 2006. Specimens were analyzed for high-risk HPV DNA using Hybrid Capture 2; of 1,028 specimens provided, 1,010 were adequate for analysis. All samples testing positive were analyzed for HPV DNA by L1 consensus polymerase chain reaction followed by type-specific hybridization. RESULTS: The overall population-based weighted estimate of high-risk HPV prevalence by Hybrid Capture 2 (Digene Corp.) was 6.0% (95% confidence interval 4.5- 7.9). Current marital and smoking status, frequency of sexual activity, history of cancer, and hysterectomy were associated with high-risk HPV positivity. Among high-risk HPV-positive women, 63% had multiple type infections. Human papillomavirus-16 or -18 was present in 17.4% of all high-risk HPV-positive women. The most common high-risk genotypes among high-risk HPV-positive women were HPV-61 (19.1%), -31 (13.1%), -52 (12.9%), -58 (12.5%), -83 (12.3%), -66 (12.0%), -51 (11.7%), -45 (11.2%), -56 (10.3%), -53 (10.2%), -16 (9.7%), and -62 (9.2%). Being married and having an intact uterus were independently associated with lower prevalence of high-risk HPV. Among unmarried women, current sexual activity and smoking were independently and positively associated with high-risk HPV infection. CONCLUSION: In this nationally representative population, nearly 1 in 16 women aged 57-85 was found to have high-risk HPV, and prevalence was stable across older age groups. LEVEL OF EVIDENCE: II.
Authors: R Herrero; A Hildesheim; C Bratti; M E Sherman; M Hutchinson; J Morales; I Balmaceda; M D Greenberg; M Alfaro; R D Burk; S Wacholder; M Plummer; M Schiffman Journal: J Natl Cancer Inst Date: 2000-03-15 Impact factor: 13.506
Authors: Philip E Castle; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Ana Cecilia Rodriguez; M Concepcion Bratti; Mark E Sherman; Sholom Wacholder; Robert Tarone; Robert D Burk Journal: J Infect Dis Date: 2005-05-02 Impact factor: 5.226
Authors: Rolando Herrero; Philip E Castle; Mark Schiffman; M Concepción Bratti; Allan Hildesheim; Jorge Morales; Mario Alfaro; Mark E Sherman; Sholom Wacholder; Sabrina Chen; Ana C Rodriguez; Robert D Burk Journal: J Infect Dis Date: 2005-05-02 Impact factor: 5.226
Authors: Philip E Castle; Mark Schiffman; M Concepcion Bratti; Allan Hildesheim; Rolando Herrero; Martha L Hutchinson; Ana Cecilia Rodriguez; Sholom Wacholder; Mark E Sherman; Hortense Kendall; Raphael P Viscidi; Jose Jeronimo; John E Schussler; Robert D Burk Journal: J Infect Dis Date: 2004-07-02 Impact factor: 5.226
Authors: M H Schiffman; H M Bauer; R N Hoover; A G Glass; D M Cadell; B B Rush; D R Scott; M E Sherman; R J Kurman; S Wacholder Journal: J Natl Cancer Inst Date: 1993-06-16 Impact factor: 13.506
Authors: Elaine M Smith; Justine M Ritchie; Barcey T Levy; Wei Zhang; Donghong Wang; Thomas H Haugen; Lubomir P Turek Journal: Cancer Detect Prev Date: 2003
Authors: Katie O'Doherty; Angela Jaszczak; Joscelyn N Hoffmann; Hannah M You; David W Kern; Kristina Pagel; Jane McPhillips; L Philip Schumm; William Dale; Elbert S Huang; Martha K McClintock Journal: J Gerontol B Psychol Sci Soc Sci Date: 2014-11 Impact factor: 4.077
Authors: Chaya Levovitz; Dan Chen; Emma Ivansson; Ulf Gyllensten; John P Finnigan; Sara Alshawish; Weijia Zhang; Eric E Schadt; Marshal R Posner; Eric M Genden; Paolo Boffetta; Andrew G Sikora Journal: Cancer Res Date: 2014-10-01 Impact factor: 12.701
Authors: Clara Bodelon; Margaret M Madeleine; Lisa G Johnson; Qin Du; Denise A Galloway; Mari Malkki; Effie W Petersdorf; Stephen M Schwartz Journal: Int J Cancer Date: 2013-08-05 Impact factor: 7.396
Authors: Rachel L Winer; James P Hughes; Qinghua Feng; Long Fu Xi; Shu-Kuang Lee; Sandra F O'Reilly; Nancy B Kiviat; Laura A Koutsky Journal: Sex Transm Dis Date: 2012-11 Impact factor: 2.830
Authors: Jessica D Bellinger; Heather M Brandt; James W Hardin; Shalanda A Bynum; Patricia A Sharpe; Dawnyéa Jackson Journal: Womens Health Issues Date: 2013-05-27